Related Experiment Video

Updated: May 16, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

L-DOPA- and graft-induced dyskinesia following transplantation

Emma L Lane1, Christian Winkler

  • 1Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK. laneel@cardiff.ac.uk

Progress in Brain Research
|December 1, 2012
PubMed

Insights

Fetal tissue transplantation for Parkinson's disease is being re-evaluated. New research clarifies how grafts affect involuntary movements and L-DOPA-induced dyskinesia in patients and animal models.

Area of Science:

  • Neuroscience
  • Regenerative Medicine
  • Clinical Neurology

Background:

  • Parkinson's disease (PD) treatment historically involved fetal tissue transplantation.
  • Graft-related abnormal involuntary movements (dyskinesia) halted progress in the early 2000s.
  • Recent advancements include patient analysis, animal models, and preclinical studies.

Purpose of the Study:

  • To review current clinical and preclinical findings on fetal tissue transplantation for Parkinson's disease.
  • To clarify the mechanisms underlying graft- and L-DOPA-induced dyskinesia.
  • To assess the graft's interaction with the host environment.

Main Methods:

  • Review of recent clinical data from transplanted Parkinson's disease patients.
  • Analysis of preclinical experimental data from animal models.
  • Examination of graft-host interactions and their impact on motor control.

Main Results:

  • Fetal tissue grafts can cause abnormal involuntary movements (dyskinesia).
  • Understanding graft-host interactions is crucial for managing dyskinesia.
  • Preclinical models aid in dissecting the causes of graft-induced dyskinesia.

Conclusions:

  • Fetal tissue transplantation for Parkinson's disease requires careful consideration of dyskinesia risks.
  • Continued research is vital to optimize transplantation strategies and mitigate side effects.
  • Future therapeutic approaches may involve refined graft protocols or alternative treatments.

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...